ESR1 and breast carcinoma: Our data, taken together, indicate that MLK activity is required for proliferation and survival of ER+ breast cancer cells, and suggest that MLK inhibitors such as CEP-1347 could be potential therapeutic agents for ER+ breast tumors, either alone or in combination with existing therapies.